Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, confirms that as previously announced it is currently undertaking meetings with investors
Open Orphan Plc announced the completion of its acquisition of UK-based hVivo Plc on Monday, 20th January 2020.
Trading update: Unaudited Revenues up 366% to £1m
Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext
On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function
The Boards of Open Orphan and hVIVO have reached an agreement on the terms of a recommended Offer to be made by Open Orphan for the entire issued and to
ImmuPharma and Avion Pharmaceuticals sign exclusive licence and development agreement and trademark agreement for Lupuzor™ with Avion to fund new international Phase III trial and commercialise in the US
The Cambridge-based pharmaceutical development company, Nuformix, were in the studio today to discuss their innovative cocrystal technology and their recent round of fundraising which brought in £1.3 million.
London: London-based medicinal cannabis company has been approved, pending ratification from the licensing Board for a medicinal cannabis Dispensary licence in Antigua and Barbuda.
Eco Equity is a pharmaceutical company that specializes in producing medicinal cannabis in Zimbabwe and the Caribbean. We speak to Jon-Paul Doran, CEO of the company to learn more about
